gemcitabine has been researched along with aprinocarsen in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belt, R; Dow, E; Figueroa, JA; Geary, R; George, S; Holmlund, J; Leonardo, J; McCachren, S; Miller, GL; Modiano, M; Oliver, JW; Otterson, GA; Ritch, P; Valdivieso, M; Villalona-Calero, MA | 1 |
1 trial(s) available for gemcitabine and aprinocarsen
| Article | Year |
|---|---|
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides, Antisense; Oligonucleotides; Oligonucleotides, Antisense; Protein Kinase C; Protein Kinase C-alpha; Thionucleotides; Treatment Outcome | 2004 |